Tranylcypromine

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instance_of gptkb:depression
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:1961
gptkb:FDA
gptkbp:atccode N06 AF01
gptkbp:available_on generic medication
gptkbp:brand Parnate
gptkbp:casnumber 155-20-2
gptkbp:chemical_formula C9 H10 N2
gptkbp:class gptkb:depression
gptkbp:clinical_trial Phase IV
gptkbp:composed_by gptkb:chemical_compound
gptkbp:contraindication gptkb:pheochromocytoma
liver disease
concurrent use of certain medications
gptkbp:dissolved soluble in water
soluble in alcohol
gptkbp:dosage_form 30 mg per day
60 mg per day
gptkbp:duration several weeks
https://www.w3.org/2000/01/rdf-schema#label Tranylcypromine
gptkbp:interacts_with gptkb:beer
tyramine
certain antidepressants
certain pain medications
gptkbp:lifespan 2 to 3 hours
gptkbp:marketed_as various pharmaceutical companies
gptkbp:mechanism_of_action inhibits monoamine oxidase
gptkbp:metabolism liver
gptkbp:notable_work impact on quality of life
long-term use effects
effects on neurotransmitters
efficacy in treatment-resistant depression
comparative studies with SSRIs
gptkbp:research_areas neuropharmacology
psychopharmacology
gptkbp:safety Category C
gptkbp:side_effect dizziness
insomnia
dry mouth
weight gain
hypertensive crisis
gptkbp:structure phenethylamine derivative
gptkbp:symptoms anxiety
fatigue
irritability
mood swings
gptkbp:used_for treatment of depression
gptkbp:bfsParent gptkb:Sunovion_Pharmaceuticals
gptkb:Monoamine_oxidase_inhibitors
gptkbp:bfsLayer 7